HopeStage
Back to all studies
CompletedNCT00639483

Celecoxib added to risperidone for schizophrenia

About this titleRead the official source — NCT00639483

This study evaluated the effectiveness of Celecoxib for people with schizophrenia.

Medication studyAges 18–50Multiple countries
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the effectiveness of Celecoxib for people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Listed locations
La Plata and 16 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMarch 2003
Recruitment status
Completed
Enrollment listed in the registry
270
Sponsor
Pfizer
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Argentina, Brazil, Germany, ...
Age range
From 18 Years to 50 Years
Official registry ID
NCT00639483
Official title
Show the full official title

A Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

La Plata, Argentina · Lanus, Argentina · PR, Brazil

12 more locations
  • Salvador, Brazil
  • Aparecida de Goiânia, Brazil
  • Rio de Janeiro, Brazil
  • São Paulo, Brazil
  • Bonn, Germany
  • München, Germany
  • Münster, Germany
  • Mexico City, Mexico
  • Mandaluyong, Philippines
  • Pasig, Philippines
  • Niao-Sung Hsiang, Taiwan
  • Taipei, Taiwan

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the effectiveness of Celecoxib for people with schizophrenia.

Who is behind this study?

The study sponsor is Pfizer.

Did this study involve medication?

Yes. The study involved medication, including Celecoxib and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies